Let G be a finite group and H a subgroup of G.The normal index of H in G is defined as the order of K/H_(G),where K is a normal supplement of H in G such that|K|is minimal and H_(G)≤K■G.Let p be a prime which divide...Let G be a finite group and H a subgroup of G.The normal index of H in G is defined as the order of K/H_(G),where K is a normal supplement of H in G such that|K|is minimal and H_(G)≤K■G.Let p be a prime which divides the order of a group G.In this paper,some characterizations of G being p-solvable or p-supersolvable were obtained by analyzing the normal index of certain subgroups of G.These results can be viewed as local version of recent results in the literature.展开更多
Let G be a finite group.A subgroup H of G is said to be σ-c-propermutable in G if G has a subgroup B such that G=N_(G)(H)B and for every Hall σ_(i)-subgroup B_(i) of B,there exists an element x∈B such that HB_(i)^(...Let G be a finite group.A subgroup H of G is said to be σ-c-propermutable in G if G has a subgroup B such that G=N_(G)(H)B and for every Hall σ_(i)-subgroup B_(i) of B,there exists an element x∈B such that HB_(i)^(x)=B_(i)^(x) H.In this paper,the influence of σ-c-propermutable subgroups on the structure of finite groups is investigated,and some criteria for a normal subgroup of G to be hypercyclically embedded in G are derived.展开更多
In this paper,we introduce the set of maximal subgroups with non-trivial core and their corresponding second maximal subgroups.A correlation characterization of the group class J_(pr)is presented by establishing the r...In this paper,we introduce the set of maximal subgroups with non-trivial core and their corresponding second maximal subgroups.A correlation characterization of the group class J_(pr)is presented by establishing the relationship between the core and the second maximal subgroups in these classifications.展开更多
目的:分析肿瘤患者输血相容性检测过程中的疑难情况,综合不同实验方法准确鉴定血型抗原和抗体,保障患者输血安全。方法:对2021年01月至2024年01月医院送检我中心的肿瘤患者血型及合血疑难样本进一步检测。血清中检出意外抗体的标本进行...目的:分析肿瘤患者输血相容性检测过程中的疑难情况,综合不同实验方法准确鉴定血型抗原和抗体,保障患者输血安全。方法:对2021年01月至2024年01月医院送检我中心的肿瘤患者血型及合血疑难样本进一步检测。血清中检出意外抗体的标本进行抗体筛查、鉴定和对应血型抗原确认;ABO疑难血型标本应用盐水试管法、吸收放散等血清学实验综合判断;疑似亚型标本提取DNA,应用序列特异性引物PCR(PCR-SSP)法进行基因检测,典型标本进行三代测序即单分子实时荧光测序(single molecule real time sequencing,SMRT)分析。结果:255例送检肿瘤患者疑难样本中,148例检出意外抗体,出现频率以抗-Lea最高(21.9%),其次为抗-E(20.6%)、抗-M(18.7%),26例样本(16.8%)未确定抗体特异性。107例样本血型鉴定困难:43例样本ABO血型复核无异常,35例样本ABO血型抗体减弱,29例样本表现为血清学亚型,其中PCR-SSP证实11例为亚型。3例典型样本血清学表现为A亚B,PCR-SSP基因分型结果分别为B(A)02/O01,B(A)04/O02,A1B;SMRT测序基因分型结果分别为ABO*BA.02/O.01.01,ABO*BA.04/O.01.02,ABO*A1.02/B.01,未发现新突变。结论:血型意外抗体、ABO血型抗原减弱及抗体减弱是构成肿瘤患者输血相容性检测疑难问题的主要原因。未来可考虑将RH和MNS血型抗原纳入献血者检测范围,并引入分子生物学技术,为患者制定个体化输血策略提供参考。展开更多
The Shenshan Group provides important geological information which is vital in unraveling the amalgamation and subsequent rifting processes of South China.While conventional studies have asserted its formation in a su...The Shenshan Group provides important geological information which is vital in unraveling the amalgamation and subsequent rifting processes of South China.While conventional studies have asserted its formation in a subduction setting,the distinct investigation reveals the necessity for reassessment.To address this,the authors employ integrated methods encompassing petrological,zircon U-Pb geochronological,Lu-Hf isotopic and geochemical methods for sedimentary rocks from the upper Shenshan subgroup and Banxi Group.The geochemical results indicate that they were formed through the recycling deposition of intermediate-acidic igneous source material and experienced moderate chemical weathering.Additionally,both sedimentary sequences exhibit characteristics consistent with those formed in an intracontinental extensional rift setting since ca.810 Ma.The provenance analysis indicates that the upper Shenshan subgroup primarily originates from the Yangtze Domain,while the Banxi Group from both the Yangtze and Cathaysia domains.Synthesizing with previous studies,the Shenshan Group should be subdivided into the lower and upper subgroups which represent distinct tectonic backgrounds.The lower subgroup is inferred to have formed in an Early Neoproterozoic fore-arc setting,akin to the Zhoutan group.The upper subgroup corresponds to the Banxi Group,representing the Middle Neoproterozoic postorogenic rift setting,responding to the breakup of Rodinia.展开更多
Cancer trials often start investigational therapy at diagnosis or after a selected number of relapses.These are the usual core inclusion criteria in clinical trials.Hence it is helpful when planning a trial to know th...Cancer trials often start investigational therapy at diagnosis or after a selected number of relapses.These are the usual core inclusion criteria in clinical trials.Hence it is helpful when planning a trial to know the likely percentages of patients receiving standard therapy at clinics and hospitals who meet this key inclusion criteria of being newly diagnosed during a period or having just had their first,second or third relapse during an anticipated enrollment time frame.Often regulatory agencies will have approvals tied to the use of a therapy in a relapsed context or in a newly diagnosed context.We provide details on calculations to help those in clinical trial operations make realistic assessments on the number of sites and likely enrollment at clinical trial sites,and the enrollment time frames that might be needed to complete planned total patient enrollment.The estimates complement site feasibility questionnaires which are often sent to gauge patient availability and site interest.展开更多
A subgroup H of a group G is called F-z-supplemented in G if there exists a subgroup K of G, such that G = HK and H∩K≤ Z∞F（G）, where Z∞F（G） is the F-hypercenter of G. We obtain some results about the F-z-suppl...A subgroup H of a group G is called F-z-supplemented in G if there exists a subgroup K of G, such that G = HK and H∩K≤ Z∞F（G）, where Z∞F（G） is the F-hypercenter of G. We obtain some results about the F-z-supplemented subgroups and use them to determine the structure of some groups.展开更多
基金Supported by the National Natural Science Foundation of China(Grant No.12071092)Guangdong Basic and Applied Basic Research Foundation(Grant No.2025A1515012072)+1 种基金the Natural Science Research Project of Anhui Educational Committee(Grant No.2024AH051298)the Scientific Research Foundation of Bozhou University(Grant No.BYKQ202419).
文摘Let G be a finite group and H a subgroup of G.The normal index of H in G is defined as the order of K/H_(G),where K is a normal supplement of H in G such that|K|is minimal and H_(G)≤K■G.Let p be a prime which divides the order of a group G.In this paper,some characterizations of G being p-solvable or p-supersolvable were obtained by analyzing the normal index of certain subgroups of G.These results can be viewed as local version of recent results in the literature.
文摘Let G be a finite group.A subgroup H of G is said to be σ-c-propermutable in G if G has a subgroup B such that G=N_(G)(H)B and for every Hall σ_(i)-subgroup B_(i) of B,there exists an element x∈B such that HB_(i)^(x)=B_(i)^(x) H.In this paper,the influence of σ-c-propermutable subgroups on the structure of finite groups is investigated,and some criteria for a normal subgroup of G to be hypercyclically embedded in G are derived.
基金Supported by the National Natural Science Foundation of China(Grant Nos.1237101812201236)+1 种基金the Fundamental Research Funds for the Central Universities(Grant No.B240201093/2013)the Natural Science Foundation of the Anhui Higher Education Institutions(Grant No.2022AH051907)。
文摘In this paper,we introduce the set of maximal subgroups with non-trivial core and their corresponding second maximal subgroups.A correlation characterization of the group class J_(pr)is presented by establishing the relationship between the core and the second maximal subgroups in these classifications.
文摘目的:分析肿瘤患者输血相容性检测过程中的疑难情况,综合不同实验方法准确鉴定血型抗原和抗体,保障患者输血安全。方法:对2021年01月至2024年01月医院送检我中心的肿瘤患者血型及合血疑难样本进一步检测。血清中检出意外抗体的标本进行抗体筛查、鉴定和对应血型抗原确认;ABO疑难血型标本应用盐水试管法、吸收放散等血清学实验综合判断;疑似亚型标本提取DNA,应用序列特异性引物PCR(PCR-SSP)法进行基因检测,典型标本进行三代测序即单分子实时荧光测序(single molecule real time sequencing,SMRT)分析。结果:255例送检肿瘤患者疑难样本中,148例检出意外抗体,出现频率以抗-Lea最高(21.9%),其次为抗-E(20.6%)、抗-M(18.7%),26例样本(16.8%)未确定抗体特异性。107例样本血型鉴定困难:43例样本ABO血型复核无异常,35例样本ABO血型抗体减弱,29例样本表现为血清学亚型,其中PCR-SSP证实11例为亚型。3例典型样本血清学表现为A亚B,PCR-SSP基因分型结果分别为B(A)02/O01,B(A)04/O02,A1B;SMRT测序基因分型结果分别为ABO*BA.02/O.01.01,ABO*BA.04/O.01.02,ABO*A1.02/B.01,未发现新突变。结论:血型意外抗体、ABO血型抗原减弱及抗体减弱是构成肿瘤患者输血相容性检测疑难问题的主要原因。未来可考虑将RH和MNS血型抗原纳入献血者检测范围,并引入分子生物学技术,为患者制定个体化输血策略提供参考。
基金supported by the National Natural Science Foundation of China(42372250,42102262 and 41972235)National Key Research and Development Program Project(2023YFF0803701)+1 种基金Southern Marine Science and Engineering Guangdong Laboratory(Zhuhai)(SML2023SP206)the program of China Scholarship Council。
文摘The Shenshan Group provides important geological information which is vital in unraveling the amalgamation and subsequent rifting processes of South China.While conventional studies have asserted its formation in a subduction setting,the distinct investigation reveals the necessity for reassessment.To address this,the authors employ integrated methods encompassing petrological,zircon U-Pb geochronological,Lu-Hf isotopic and geochemical methods for sedimentary rocks from the upper Shenshan subgroup and Banxi Group.The geochemical results indicate that they were formed through the recycling deposition of intermediate-acidic igneous source material and experienced moderate chemical weathering.Additionally,both sedimentary sequences exhibit characteristics consistent with those formed in an intracontinental extensional rift setting since ca.810 Ma.The provenance analysis indicates that the upper Shenshan subgroup primarily originates from the Yangtze Domain,while the Banxi Group from both the Yangtze and Cathaysia domains.Synthesizing with previous studies,the Shenshan Group should be subdivided into the lower and upper subgroups which represent distinct tectonic backgrounds.The lower subgroup is inferred to have formed in an Early Neoproterozoic fore-arc setting,akin to the Zhoutan group.The upper subgroup corresponds to the Banxi Group,representing the Middle Neoproterozoic postorogenic rift setting,responding to the breakup of Rodinia.
文摘Cancer trials often start investigational therapy at diagnosis or after a selected number of relapses.These are the usual core inclusion criteria in clinical trials.Hence it is helpful when planning a trial to know the likely percentages of patients receiving standard therapy at clinics and hospitals who meet this key inclusion criteria of being newly diagnosed during a period or having just had their first,second or third relapse during an anticipated enrollment time frame.Often regulatory agencies will have approvals tied to the use of a therapy in a relapsed context or in a newly diagnosed context.We provide details on calculations to help those in clinical trial operations make realistic assessments on the number of sites and likely enrollment at clinical trial sites,and the enrollment time frames that might be needed to complete planned total patient enrollment.The estimates complement site feasibility questionnaires which are often sent to gauge patient availability and site interest.
文摘A subgroup H of a group G is called F-z-supplemented in G if there exists a subgroup K of G, such that G = HK and H∩K≤ Z∞F（G）, where Z∞F（G） is the F-hypercenter of G. We obtain some results about the F-z-supplemented subgroups and use them to determine the structure of some groups.
